Literature DB >> 11121837

Novel approaches to targeting neuropeptide systems.

B P Roques1.   

Abstract

Generation and/or interruption of cell signalling by neuropeptides has been shown to be essentially, although not exclusively, mediated by one or several membrane-bound enzymes, giving rise to the concept of selective versus dual enzyme inhibitors. Because most of these enzymes are zinc metallopeptidases, novel inhibitors are now being designed based on the structure of these proteins. The physiological role of neuropeptides and their relationships with other peptide systems can be investigated by comparing results obtained using peptidase inhibitors and selective receptor antagonists with those obtained using mice in which genes encoding the various components of a peptide system have been deleted. The potential use of peptidase inhibitors, compared with exogenous agonists, as therapeutic agents (particularly as analgesics or antidepressants) and their use in the investigation of the neurobiology of drug abuse will be discussed with particular focus on enkephalins and cholecystokinin 8 (CCK-8).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121837     DOI: 10.1016/s0165-6147(00)01571-6

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  21 in total

1.  Extracellular peptidase activity tunes motor pattern modulation.

Authors:  Debra E Wood; Michael P Nusbaum
Journal:  J Neurosci       Date:  2002-05-15       Impact factor: 6.167

Review 2.  Endogenous signaling complexity in neuropeptides- leucine- and methionine-enkephalin.

Authors:  Walter J Lukiw
Journal:  Cell Mol Neurobiol       Date:  2006-06-27       Impact factor: 5.046

3.  Peptidases prevent mu-opioid receptor internalization in dorsal horn neurons by endogenously released opioids.

Authors:  Bingbing Song; Juan Carlos G Marvizón
Journal:  J Neurosci       Date:  2003-03-01       Impact factor: 6.167

4.  Structure-activity studies with high-affinity inhibitors of pyroglutamyl-peptidase II.

Authors:  Julie A Kelly; Gaia A Scalabrino; Gillian R Slator; Aoife A Cullen; John F Gilmer; David G Lloyd; Geoffrey W Bennett; Karl Bauer; Keith F Tipton; Carvell H Williams
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

5.  A cholecystokinin B receptor antagonist and cocaine interaction, phase I study.

Authors:  Ahmed Elkashef; James Robert Brašić; Louis R Cantelina; Roberta Kahn; Nora Chiang; Weiguo Ye; Yun Zhou; Jurij Mojsiak; Kimberly R Warren; Andrew Crabb; John Hilton; Dean F Wong; Frank Vocci
Journal:  CNS Neurosci Ther       Date:  2018-06-20       Impact factor: 5.243

6.  Stage-specific modulation of neprilysin and aminopeptidase N in the limbic system during kindling progression.

Authors:  Patricia de Gortari; Miguel Angel Vargas; Adrián Martínez; Arlene I García-Vázquez; Rosa María Uribe; Lucía Chávez-Gutiérrez; Víctor Magdaleno; Guy Boileau; Jean-Louis Charlí; Patricia Joseph-Bravo
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

7.  Enkephalins, dynorphins, and beta-endorphin in the rat dorsal horn: an immunofluorescence colocalization study.

Authors:  Juan Carlos G Marvizón; Wenling Chen; Niall Murphy
Journal:  J Comp Neurol       Date:  2009-11-01       Impact factor: 3.215

8.  Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine.

Authors:  Inge Sillaber; Markus Panhuysen; Markus S H Henniger; Frauke Ohl; Claudia Kühne; Benno Pütz; Thomas Pohl; Jan M Deussing; Marcelo Paez-Pereda; Florian Holsboer
Journal:  Psychopharmacology (Berl)       Date:  2008-07-16       Impact factor: 4.530

9.  Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects.

Authors:  Huina Zhang; Mary M Torregrossa; Emily M Jutkiewicz; Yong-Gong Shi; Kenner C Rice; James H Woods; Stanley J Watson; M C Ko
Journal:  Eur J Neurosci       Date:  2006-02       Impact factor: 3.386

10.  Peripheral non-viral MIDGE vector-driven delivery of beta-endorphin in inflammatory pain.

Authors:  Halina Machelska; Matthias Schroff; Detlef Oswald; Waltraud Binder; Nicolle Sitte; Shaaban A Mousa; Heike L Rittner; Alexander Brack; Dominika Labuz; Melanie Busch; Burghardt Wittig; Michael Schäfer; Christoph Stein
Journal:  Mol Pain       Date:  2009-12-14       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.